ERBB2 and neoplasm: For example, extensive research on trastuzumab and cetuximab in non-clinical studies suggested mAb action beyond signaling inhibition, which include receptor downregulation, degradation (in case of cetuximab), decrease in angiogenic factors, reduced production of active truncated HER2 (p95) fragments via inhibition of HER2 cleavage (in case of trastuzumab) 27, 28, 29 and ADCC dependent killing of tumor cells 30.